UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Inari Medical, Inc.

(Exact name of Registrant as Specified in Its Charter)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Item 5.02(d)

Effective as of October 1, 2021, the Board of Directors (the “Board”) of Inari Medical, Inc., a Delaware corporation (the “Company”) increased the size of the Board from seven (7) directors to eight (8) directors and appointed Dana G. Mead, Jr. as a new Class II member of the Board and as a member of the Compensation Committee of the Board. Mr. Mead’s term of office as a Class II Director will expire at the Company’s 2022 annual meeting of stockholders or until his successor has been elected and qualified or his earlier death, resignation or removal. The Board has determined that Mr. Mead is an “independent director” as defined under the applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) and the listing requirements and rules of the Nasdaq stock market, and is a “non-employee director” under Section 16 of the Exchange Act of 1934, as amended.

From May 2019 to February 2021, Mr. Mead served as President and CEO of HeartFlow, Inc., a medical device company located in Redwood City, CA. From November 2016 to May 2019, Mr. Mead served as the President and Chief Executive Officer of Beaver-Visitec International, a medical device company located in Waltham, MA. Previously, Mr. Mead was a Strategic Advisor and Partner at Kleiner Perkins Caufield & Byers, a venture capital firm, having joined the firm in May 2005 and serving until June 2016. Mr. Mead was at Guidant Corporation, a cardiovascular medical device company, from 1992 to 2005, most recently as President, Guidant Vascular Intervention. Since July 2008, Mr. Mead has served as a member of the board of directors of Inspire Medical Systems, Inc., a NYSE listed medical technology company. Since February 2010, Mr. Mead has served on the board of directors of Pulmonx Corporation, a NASDAQ listed medical device company, and since June 2007 on the board of directors of Intersect ENT, Inc., a NASDAQ listed medical device company. Mr. Mead served on the board of directors of Teladoc, Inc., a NYSE listed telehealth platform company, from August 2011 to December 2016. Mr. Mead holds a B.A. from Lafayette College and an M.B.A. from the University of Southern California.

Mr. Mead will be compensated in a manner consistent with the Company’s other non-employee directors, as described under the heading “Director Compensation” in the Company’s definitive proxy statement filed with the SEC on April 16, 2021.

There are no arrangements or understandings between Mr. Mead and any other persons pursuant to which he was appointed as a director. Furthermore, there are no transactions in which Mr. Mead has an interest that would be required to be reported under Item 404(a) of Regulation S-K.

Item 7.01 Regulation FD Disclosure.

On October 1, 2021, the Company issued a press release announcing the appointment of Mr. Mead. A copy of the press release is attached hereto as Exhibit 99.1.

The information contained in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.